Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influence of novel CYP2C-haplotype on proton pump inhibitor pharmacokinetics in children.

Clinical and translational science - 1 Apr 2024

Kyler Kathryn E, Gaedigk Andrea, Abdel-Rahman Susan, Staggs Vincent S, Pearce Robin E, Toren Paul, Leeder J Steven, Shakhnovich Valentina

Abstract excerpt

In this brief report, we provide an analysis of the influence of a novel CYP2C haplotype (CYP2C:TG) on proton pump inhibitor (PPI) pharmacokinetics (PK) in children. The CYP2C:TG haplotype has been proposed to be associated with increased CYP2C19 activity. We sought to determine if this CYP2C:TG haplotype resulted in similar alterations in metabolism for proton pump inhibitors, which are primarily metabolized by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C19

Share to Cytochrome P-450 Enzyme System

Share to Genotype

Share to Haplotypes

Share to Proton Pump Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 38629502
DOI: 10.1111/cts.13782
PMCID: PMC11022290

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influence of novel CYP2C-haplotype on proton pump inhibitor pharmacokinetics in children.PMID 38629502Read ↗

New Guidance on Cytochrome P450 2C19 Phenotype-based Use of Proton Pump Inhibitors.Semantic proximity Read ↗

Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.Semantic proximity Read ↗

CYP2C19 genotype-guided dosing of proton pump inhibitors: progress in clinical trials and real-world use.Semantic proximity Read ↗

New perspectives in gastric acid suppression: genetic polymorphisms predict the efficacy of proton pump inhibitors.Semantic proximity Read ↗

Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problemSemantic proximity Read ↗

Pharmacogenomic testing: the case for CYP2C19 proton pump inhibitor gene-drug pairs.Semantic proximity Read ↗

Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians.Semantic proximity Read ↗

Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.Semantic proximity Read ↗

Genetic polymorphism of CYP2C19 & therapeutic response to proton pump inhibitors.Semantic proximity Read ↗

CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection.Semantic proximity Read ↗

CYP2C19 Phenotype and Risk of Proton Pump Inhibitor-Associated Infections.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.